Sun Pharmaceutical Industries Ltd

🌍 Sun Pharma to Acquire Organon for $11.75B, Expanding Global Reach to 140 Countries

• Sun Pharma acquires Organon for $14.00 per share in an all-cash deal with an enterprise value of $11.75 billion.

• The acquisition is expected to close in early 2027, pending approvals.

• Combined company projected revenue reaches $12.4 billion, positioning Sun Pharma among the top 25 global pharmaceutical firms.

• Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for the year ended December 31, 2025.

• Sun Pharma will fund the transaction using cash reserves and committed bank financing.

• The deal strengthens Sun Pharma's focus on women's health, biosimilars, and established branded medicines.

• Organon brings a portfolio of over 70 products, operates in 140 countries, and employs approximately 10,000 people.

• Post-acquisition, Sun Pharma anticipates nearly doubled EBITDA and cash flow, with a net debt/EBITDA ratio of 2.3x.